Shield Therapeutics Plc

(LSE) STX

Current Price£0.06

Market Cap£68.45M

Since IPO (2016)-96%

5 Year-88%

1 Year+161%

1 Month-5%

Shield Therapeutics Plc Financials at a Glance

Market Cap

£68.45M

Revenue (TTM)

$82.65M

Net Income (TTM)

-$45.08M

EPS (TTM)

-£0.01

P/E Ratio

-5.00

Dividend

£0.00

Beta (Volatility)

-0.09 (Low)

Dividend

£0.00

Beta (Volatility)

-0.09 (Low)

Price

£0.06

Volume

479,983

Open

£0.06

Price

£0.06

Volume

479,983

Open

£0.06

Previous Close

£0.06

Daily Range

£0.06 - £0.06

52-Week Range

£0.02 - £0.13

Estimated Earnings Date

Sep 3, 2026

Dividend

£0.00

Beta (Volatility)

-0.09 (Low)

Price

£0.06

Volume

479,983

Open

£0.06

Previous Close

£0.06

Daily Range

£0.06 - £0.06

52-Week Range

£0.02 - £0.13

Estimated Earnings Date

Sep 3, 2026

STX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Shield Therapeutics Plc

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Karl Anders Lundström

Website

www.shieldtherapeutics.com

Headquarters

Gateshead, NE8 3DF, GB

STX Financials

Key Financial Metrics (TTM)

Gross Margin

44%

Operating Margin

-20%

Net Income Margin

-36%

Return on Equity

Return on Capital

-69%

Return on Assets

-28%

Earnings Yield

-20.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£68.45M

Shares Outstanding

1.07B

Volume

479.98K

Avg. Volume

2.48M

Financials (TTM)

Gross Profit

$22.38M

Operating Income

-$10.30M

EBITDA

-$9.16M

Operating Cash Flow

-$8.81M

Capital Expenditure

-$24.50K

Free Cash Flow

-$8.83M

Cash & ST Invst.

$11.63M

Total Debt

$30.15M

Shield Therapeutics Plc Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$28.39M

+221.6%

Gross Profit

$12.10M

+874.6%

Gross Margin

42.63%

N/A

Market Cap

£68.45M

N/A

Market Cap/Employee

£1.09M

N/A

Employees

N/A

Net Income

-$8.16M

+60.9%

EBITDA

-$3.96M

+80.0%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Total Cash

$11.63M

-15.9%

Total Debt

$30.15M

+47.8%

Accounts Receivable

$24.39M

+119.3%

Inventory

$9.22M

+190.2%

Long Term Debt

$30.15M

+51.4%

Short Term Debt

$0.00

-100.0%

Return on Assets

-27.96%

N/A

Return on Invested Capital

-69.31%

N/A

Free Cash Flow

-$13.02M

+30.7%

Operating Cash Flow

-$13.00M

+25.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SCLP.LScancell Holdings plc

SCLP.LScancell Holdings plc£0.21+1.22%

SPEC.LINSPECS Group plc

SPEC.LINSPECS Group plc£1.01+4.15%

VLG.LVenture Life Group plc

VLG.LVenture Life Group plc£0.67-0.75%

CREO.LCreo Medical Limited

CREO.LCreo Medical Limited£0.14-0.91%

BVC.LBATM Advanced Communications Ltd.

BVC.LBATM Advanced Communications Ltd.£0.14-2.81%

EAH.LECO Animal Health Group plc

EAH.LECO Animal Health Group plc£0.89-2.73%

HEMO.LHemogenyx Pharmaceuticals Plc

HEMO.LHemogenyx Pharmaceuticals Plc£7.97+2.44%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$15.94+0.03%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$83.05+0.07%

SMCISuper Micro Computer

SMCISuper Micro Computer$30.33+0.09%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$36.73-0.07%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$35.51-0.02%

INTCIntel

INTCIntel$134.10+0.11%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$179.75-0.06%

Questions About STX

What is the current price of Shield Therapeutics Plc?

Shield Therapeutics Plc is trading at £0.06 per share.

What is the 52-week range for Shield Therapeutics Plc?

Over the past 52 weeks, Shield Therapeutics Plc has traded between £0.02 and £0.13.

How much debt does Shield Therapeutics Plc have?

As of the most recent reporting period, Shield Therapeutics Plc reported total debt of $22.40M.

How much cash does Shield Therapeutics Plc have on hand?

Shield Therapeutics Plc reported $8.64M in cash and cash equivalents in its most recent financial results.

What is Shield Therapeutics Plc’s dividend yield?

Shield Therapeutics Plc does not currently have a dividend yield.

Shield Therapeutics Plc

Shield Therapeutics Plc Financials at a Glance

STX News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Shield Therapeutics Plc

STX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Shield Therapeutics Plc Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About STX

What is the current price of Shield Therapeutics Plc?

What is the 52-week range for Shield Therapeutics Plc?

How much debt does Shield Therapeutics Plc have?

How much cash does Shield Therapeutics Plc have on hand?

What is Shield Therapeutics Plc’s dividend yield?

Premium Investing Services